Janux Therapeutics’ (JANX) Buy Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright reaffirmed their buy rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently have a $63.00 price objective on the stock.

A number of other equities research analysts have also issued reports on the stock. UBS Group assumed coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday. Stifel Nicolaus began coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 target price for the company. Finally, Scotiabank reduced their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.44.

Check Out Our Latest Stock Analysis on JANX

Janux Therapeutics Trading Down 0.5 %

JANX stock opened at $53.92 on Thursday. Janux Therapeutics has a 12-month low of $5.65 and a 12-month high of $65.60. The business’s 50-day moving average is $49.02 and its 200 day moving average is $46.36. The stock has a market cap of $2.81 billion, a price-to-earnings ratio of -46.09 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.95%. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The business’s revenue was down 82.6% compared to the same quarter last year. As a group, equities analysts forecast that Janux Therapeutics will post -1.18 EPS for the current fiscal year.

Insider Buying and Selling

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $46.24, for a total transaction of $44,297.92. Following the completion of the sale, the insider now directly owns 6,887 shares in the company, valued at $318,454.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The shares were purchased at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the acquisition, the director now owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the firm’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the transaction, the insider now owns 6,887 shares of the company’s stock, valued at $318,454.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 420,610 shares of company stock valued at $19,288,666. 29.40% of the stock is currently owned by insiders.

Institutional Trading of Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Logos Global Management LP grew its holdings in shares of Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Janux Therapeutics in the first quarter worth $20,420,000. Vanguard Group Inc. increased its position in shares of Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after acquiring an additional 378,477 shares during the period. Altitude Crest Partners Inc. acquired a new stake in shares of Janux Therapeutics in the first quarter valued at $7,278,000. Finally, Point72 Asset Management L.P. purchased a new position in Janux Therapeutics in the second quarter valued at $5,715,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Further Reading